EUVIMEDEUVIMED entdecken
Crossref

Stereotactic Arrhythmia Radioablation of Recurrent Ventricular Tachycardia in Structural Heart Disease

Jana Hašková, Josef Kautzner, Marek Šramko, Petr Peichl, Lukáš Knybel, Otakar Jiravský, Radek Neuwirth, Josef Marek, Jiří Plášek, Jakub Cvek, Dan Wichterle

JACC: Clinical Electrophysiology · 2026-08

DOI: 10.1016/j.jacep.2026.06.043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2026-08. Verfasst von Jana Hašková und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia; Faculty of Medicine and Dentistry, Palacký University, O…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Ministry of Health of the Czech Republic, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Stereotactic arrhythmia radioablation (STAR) has been proposed to treat refractory ventricular tachycardia (VT) in patients with structural heart disease (SHD). OBJECTIVES: The aim of the STAR-VT-2020 (Stereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease) randomized trial was to compare the efficacy of STAR and catheter ablation (CA) after a failure of previous CA. METHODS: Patients with VT recurrences were randomized at 2 centers (June 2020 to January 2024) to the STAR or CA group in a 1:1 fashion using a covariate-adaptive algorithm. In the STAR group, the arrhythmogenic substrate was irradiated by a single dose of 25 Gy delivered by a robotic system (CyberKnife). The planning target volume was delineated by coregistering the electroanatomical substrate map (CARTO 3) with the planning computed tomographic scan. In the CA group, CA was performed using substrate modification strategies. The primary endpoint was VT recurrence, while repeated CA was one of the secondary endpoints. RESULTS: A total of 22 patients (68% men, mean age 67 ± 11 years, 27% with ischemic cardiomyopathy, mean left ventricular ejection fraction 31% ± 9%, 3.0 ± 1.3 previous CAs) were enrolled (11 in each group) and followed for 28 ± 17 months. The STAR patients exhibited a nonsignificantly higher risk for VT recurrence (HR: 2.5; 95% CI: 0.97-6.6) than those who underwent CA, and a significantly higher risk of repeated CA for VT (HR: 4.0; 95% CI: 1.2-13.8). Throughout the trial, 13 patients died, 3 underwent heart transplantation, and 3 received left ventricular assist devices, with no significant differences between the 2 groups. CONCLUSIONS: The STAR-VT-2020 trial suggests a potential clinical benefit of repeated CA over STAR in patients with SHD, despite prior failed CA at specialized centers. Because of the small study cohort of highly selected patients and several methodological limitations, the results of the prematurely terminated trial should be considered exploratory and interpreted strictly as hypothesis generating. Larger trials with optimized design are warranted. (Stereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease; NCT04612140).

Schlagwörter

Stichwörter der Autor:innen

catheter ablationcomplicationsstereotactic arrhythmia radioablationventricular tachycardia

Autor:innen und Institutionen

  • Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia; Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czechia.
  • Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
  • Department of Oncology, University Hospital Ostrava and Ostrava University Medical School, Ostrava, Czechia.
  • Department of Cardiology, Hospital AGEL Třinec-Podlesí, Třinec, Czechia; Faculty of Medicine, Masaryk University, Brno, Czechia.
  • Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia; Department of Cardiology, University Hospital Ostrava and Ostrava University Medical School, Ostrava, Czechia.
  • Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia; 2nd Department of Medicine, Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University, Prague, Czec…

Förderung

  • Ministry of Health of the Czech Republic
  • European Research Council

Zitieren

APA

Hašková, J., Kautzner, J., Šramko, M., Peichl, P., Knybel, L., Jiravský, O., Neuwirth, R., Marek, J., Plášek, J., Cvek, J., & Wichterle, D. (2026). Stereotactic Arrhythmia Radioablation of Recurrent Ventricular Tachycardia in Structural Heart Disease. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2026.06.043

Vancouver

Hašková J, Kautzner J, Šramko M, Peichl P, Knybel L, Jiravský O, et al. Stereotactic Arrhythmia Radioablation of Recurrent Ventricular Tachycardia in Structural Heart Disease. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2026.06.043

BibTeX
@article{Hakov2026,
  author = {Hašková, Jana and Kautzner, Josef and Šramko, Marek and Peichl, Petr and Knybel, Lukáš and Jiravský, Otakar and Neuwirth, Radek and Marek, Josef and Plášek, Jiří and Cvek, Jakub and Wichterle, Dan},
  title = {Stereotactic Arrhythmia Radioablation of Recurrent Ventricular Tachycardia in Structural Heart Disease},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  doi = {10.1016/j.jacep.2026.06.043}
}
Kostenlos starten →